Why the study?
Lipid metabolism may impact disability in people with multiple sclerosis.
Does a pathology-supported genetic testing program improve disability in people with multiple sclerosis?
Does a pathology-supported genetic testing program improve disability in people with multiple sclerosis?
Pathology-supported genetic testing may guide lifestyle interventions to improve disability outcomes in multiple sclerosis.
Answers are grounded in this paper and cite their sources.
Should not yet change MS practice; hypothesis-generating for pathology-supported genetic testing and requires randomized confirmation.
Background: Lipid metabolism may impact disability in people with multiple sclerosis (pwMS). Methods: Fifty-one pwMS entered an ultrasound and MRI study, of whom 19 had followed a pathology-supported genetic testing program for more than 10 years (pwMS-ON). Genetic variation, blood biochemistry, vascular blood flow velocities, diet and exercise were investigated. Results: PwMS-ON had significantly lower (p < 0.01) disability (Expanded Disability Status Scale) than pwMS not on the program (1.91 ± 0.75 vs 3.87 ± 2.32). A genetic variant in the lipid transporter FABP2 gene (rs1799883; 2445G>A, A54T) was significantly associated (p < 0.01) with disability in pwMS not on the program, but not in pwMS-ON (p = 0.88). Vascular blood flow velocities were lower in the presence of the A-allele. Conclusion: Pathology-supported genetic testing may provide guidance for lifestyle interventions with a significant impact on improved disability in pwMS.
No takes yet. Share an insight, caveat, or question.
Johannes et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: